Introduction
It is estimated that in 1998, 12,300 new cases of esophageal cancer will be diagnosed and nearly 11,900 deaths will occur.
1 Despite these alarming numbers, treatment of esophageal cancer has been the focus of several studies in the last decade as new treatment strategies evolve. Radiation therapy plays an important role in the combined modality treatment of esophageal cancer. The following highlights the various clinical studies that have led to this current thinking.
Natural History of Esophageal Cancer
Esophageal cancers have extensive local growth and lymph node involvement before widespread dissemination. 2 Small lymphatic channels arise within the mucosa and external muscular coat of the esophagus and drain into larger lymphatic channels located in the submucosa and muscular layers of the esophagus. 2 The dual longitudinal interconnecting lymphatic supply of the esophagus provides a submucous pathway for the lymphatic dissemination of cancer into a large number of widely separate collections of lymph nodes. 2, 3 Viable tumor emboli may block a lymphatic branch and give rise to a secondary deposit that presents as a submucosal outcropping, sometimes as much as 8 cm distant from the primary cancer. 3 The lack of a serosal lining often leads to transesophageal spread of disease into the adjacent viscera and blood vessels. The disease causes death by both local growth and distant metastases. Distant metastases have been noted in virtually every tissue, including lymph nodes (73%), lung (52%), liver (47%), adrenals (20%), stomach (15%), bones (14%), and kidneys (13%) ( Table 1) . 4 
Epidemiology
Between 1973 and 1982, the overall incidence rate per 100,000 population was 2.6 for squamous-cell carcinoma (SCC) and 0.4 for adenocarcinoma. The incidence of SCC in black men and women increased by 30% between 1973 and 1982, and the rate of adenocarcinoma among white men increased by 74%. 5 By 1990, adenocarcinomas were the predominant esophageal cancers among white men. 6 The risk factors associated with SCC include tobacco use, alcohol use, presence of food preservatives such as nitrosamines, and caustic strictures. 7 Dietary factors, viral agents, genetic predisposition, and exposure to ionizing radiation have also been implicated. 7 Barrett's esophagus is a risk factor for adenocarcinoma. 7 Clinical reports suggest that patients with esophageal adenocarcinoma have a higher incidence of hiatal hernia and duodenal ulcer compared to patients with gastric cancer. 8 A more detailed review is beyond the scope of this article.
Patterns of Failure
The autopsy series by Appelqvist 9 noted the cause of death in esophageal cancer to be a local cause 2.28 times as often as a metastatic cause. Mandard et al 10 reported that in 60% of the previously treated patients in their autopsy series, the neoplasm had spread beyond the esophageal wall and involved neighboring structures, thus supporting the importance of locoregional control. Distant nonnodal metastases are documented in approximately 17% to 69% of patients in other series. 10 ,11 Table 2 displays the results of patterns of failure after radiation therapy and surgery as quoted by Aisner et al. 4 
Surgery
Surgery has a role in both curative and palliative management of esophageal carcinoma. In advanced disease, it offers the quickest palliation for dysphagia. A review of the data from approximately 122 series with 83,783 patients by Earlam and Cunha-Melo 12 revealed that the five-year survival rates was 4 ± 3% (mean ± 1 SD), with an operation rate of 58 ± 24% (mean ± 1 SD), resection rate of 39 ± 22% (mean ± 1 SD), and a resection mortality of 29 ± 16% (mean ± 1 SD). Contemporary clinical trials report decreases in the surgical mortality and improvements in resectability. 13, 14 
Radiation Therapy
Radiation therapy has been used definitively, both preoperatively and postoperatively. It has been delivered mainly as external-beam radiation therapy (teletherapy), with endoluminal therapy (brachytherapy) being used as a boost to initial therapy.
Radiation Therapy Alone
The British Medical Research Council Trial, 15 which attempted to answer questions comparing radiation therapy alone vs surgery, was closed due to poor accrual. Definitive radiation therapy alone in doses of 50 to 70 Gy produces a median survival duration of less than 12 months and a five-year survival of less than 10% in the majority of series. 16 -19 Earlam and Cunha-Melo 20 reviewed 49 series with 8,489 patients treated with radiation alone and found the survival rates to be 18% at 1 year, 8% at 2 years, and 6% at 5 years. Table 3 shows the results that have been obtained by various investigators. Jun et al 21, 22 analyzed various radiation treatment schemes and noted no survival benefit to different radiation schemes. Accelerated fractionation schemes that decrease overall treatment time may enhance local control, although esophageal stenosis, a late effect of this modality, is more commonly observed as noted by Nishimura et al. 23 Recent clinical trials have shown radiotherapy as a sole modality to be inferior to chemoradiation. Nevertheless, patients who are poor surgical risks and are unable to tolerate chemotherapy occasionally will need to be managed with radiation therapy alone with a small but real chance of survival.
Radiation Therapy Planning Principles
Position: Patient positioning in the prone position is preferable in thoracic lesions and is likely to move the esophagus further from the spinal cord. Localization: The use of barium paste after ensuring that there is no aspiration helps to delineate lesions. Target volume: The tumor volume is defined by the largest volume indicated by endoscopic findings, esophageal ultrasound, barium series, computed tomography (CT) scans, or magnetic resonance imaging (MRI) scans. A margin of 5 cm or more beyond the gross primary disease superiorly and inferiorly should be used. Portals must be wide enough to include all the gross disease with 2-cm margins. Inclusion of the supraclavicular fossa should be considered, especially when the tumor extends above the carina. If the tumor is in the distal third or the celiac nodes are histologically or clinically positive, the target volume is enlarged to include this nodal volume. CT/MRI scans should be used to define the celiac axis nodes. Contours of the neck and body, as appropriate, should be obtained if CT-based treatment planning facilities are not available. CT-based treatment planning is done in the same position as simulation and provides more information about the extent of extraesophageal disease than do barium studies. The use of complex field arrangement with the use of wedges, compensators, field weighting, and bolus will help to decrease the risk of complications while ensuring adequate coverage of the target volume. Dosemetric evaluation: Doses to the spinal cord, heart, lungs, liver, and kidneys must be kept within the tolerance limits to reduce sequelae and morbidity. Dose: A wide range of doses has been used with radiotherapy alone and will be a function of the tumor location and the normal tissue tolerance. We usually attempt to deliver a dose of at least 65 Gy in 1.8 to 2.0 Gy fractions.
Preoperative Radiotherapy Alone
The rationale for the use of preoperative radiotherapy is to increase resectability, decrease the locoregional failure, and thus increase the long-term survival. However, the results of five randomized trials (Table 4) , 24 -28 including the European Organization for Research on Treatment of Cancer (EORTC) trial, 24 did not show any obvious increase in resectability or survival. It should be noted that because the doses used in these studies were lower than doses commonly used today and the interval from completion of radiotherapy to surgery was also shorter than currently employed, meaningful conclusions are difficult to obtain.
Postoperative Radiotherapy Alone
Adjuvant postoperative radiotherapy has been used to decrease the risk of locoregional recurrence and to attempt to improve survival. Kasai et al 29 reported that prophylactic postoperative radiation therapy improved survival in those patients who underwent a curative resection and those who did not have lymph nodal metastases. However, the two randomized studies by Teniere et al 30 and Fok et al 31 do not reflect any improvement in five-year survival. In the Teniere study, survival in patients was not influenced by postoperative radiation therapy. The rates of local or regional recurrence were lower in the group that received postoperative radiotherapy compared with those who received surgery alone (85% vs 70%, respectively, surviving without recurrence at five years). The difference between the rates of local or regional recurrence was statistically significant in the node-negative (N0) stratum only. The study by Fok and colleagues 31 noted a 37% incidence of stomach (neoesophagus) complications, including gastritis and gastrointestinal hemorrhage, with 8% treatment-related fatality in the irradiated group. This may be related to the high dose per fraction (3.5 Gy) used in this trial. Table 5 briefly reviews the results of these studies.
Brachytherapy
Intraluminal brachytherapy has been used to provide a boost to the tumor with radioactive sources being introduced by a nasogastric tube introduced into the esophagus. The rapid fall of dose as the distance from the central axis of the source increases does not allow the delivery of adequate dose to the paraesophageal lymphatics. However, in lesions that are truly localized to the esophagus, this modality may be used to deliver a boost to the primary tumor of limited thickness. Various institutions have used this modality to deliver a boost using low-dose-rate (LDR) and fractionated high-dose-rate (HDR) techniques. The wide variations in the indications, prescribed doses, and dosimetry have led to the development of guidelines (Table 6 ) from the American Brachytherapy Society. 32 Complications associated with this modality include perforation, aspiration pneumonitis, esophageal bleeding and mediastinitis, and development of strictures. The preliminary report of the Radiation Therapy Oncology Group (RTOG) study 92-07 33 observed a 34% incidence of life-threatening toxicity or treatment-related mortality when intraluminal HDR therapy was used with concurrent chemotherapy after external-beam radiotherapy. This prompted a word of caution from the investigators regarding the use of this modality in conjunction with teletherapy and concurrent chemotherapy.
The 34 compared adjuvant chemotherapy given both preoperatively and postoperatively vs surgery alone and did not find any significant difference in the resectability rates or in the actuarial survival of their patients. The median survival for patients responding to chemotherapy was longer than 20 months, whereas patients not responding to chemotherapy had a median survival of 6.2 months, which was statistically significant (P=0.008). The survival of responders was also significantly longer than that of the patients in the surgery group (P=0.05). The closed Intergroup trial (INT-0113) 35 compared neoadjuvant cisplatin and 5-fluorouracil (5-FU) for three cycles followed by two more cycles after resection vs surgery alone in randomized 467 patients. Preliminary analysis reports that 61% of the patients received all three cycles of planned chemotherapy, and 20% had grade 3 or 4 hematologic toxicity. Early results have failed to reveal any median survival difference.
Concurrent Chemoradiation
The studies of Byfield et al 36 Gy with the same chemotherapy. The overall median survival of stage I/II patients was 18 months, with three-and five-year actuarial survival of 29% and 18%, respectively. The actuarial-determined relapse-free rate for stage I and II at both 3 and 5 years was 70%. The median survival of patients with stage III and IV disease was 9 months and 7 months, respectively. Significantly, palliation was rendered to patients with advanced disease with relief of dysphagia in 77%, with 60% being free of dysphagia at the time of death. Severe acute reactions were noted in 11 (12.2%) patients. Three (3.3%) patients developed significant late toxicity requiring hospitalization with 2 (2.2%) treatment-related fatalities.
Four randomized studies evaluating definitive chemoradiation vs radiation alone have been completed recently ( Table 8 ). The recently published ECOG EST-1282 trial 40 reports improved overall survival of patients with SCC of the esophagus compared to those treated with radiation alone. The median two-year and five-year survival for the combined modality treatment was 14.8 months (27% and 9%, respectively) compared to 9.2 months (33% and 7%, respectively) for the radiation arm. Interestingly, the study also reports that surgery that was optional on the treatment protocol had a marginally significant impact on survival. An update of the RTOG study 85-01, 41 which compared chemotherapy and radiotherapy vs radiotherapy alone in patients with locally advanced esophageal cancer, was recently published. Two courses of chemotherapy (CT) during 50 Gy radiation therapy (RT) followed by additional two courses of the same CT vs 64 Gy RT alone were investigated. CT consisted of cisplatin 75 mg/m 2 on day 1 and 5-FU 1000 mg/m 2 per day on days 1 to 4 every 4 weeks with RT and every 3 weeks post-RT. The main objective of the study was to compare overall survival between the two randomized treatment groups. Sixty-two patients were randomized to receive RT alone and 61 were randomized to the combined arm. The minimum follow-up was five years for all patients. In the combined-treatment group, the median survival duration was 14.1 months and the five-year survival rate was 27%, while in the RT-alone group, the median survival duration was 9.3 months with no patients alive at 5 years (P<.0001). Fewer local failures and distant recurrences were also noted in the combined-modality group in this study. 41 The study concluded that cisplatin and 5-FU infusion given during and following RT of 50 Gy is statistically superior to standard 64-Gy RT alone in patients with locally advanced esophageal cancer. In the EORTC study 42 in addition to the above, the progression-free survival advantage was statistically significant. All four studies report a superior median survival in the chemoradiation arm vs radiation alone. Thus, definitive chemoradiation vs radiation alone appears to provide an improved therapeutic outcome.
Locoregional 4 and 29-32 ) and mitomycin C (day 1) followed by surgery (day 49-64). Postoperatively, 20 Gy was delivered to patients with residual disease. Follow-up revealed that four of the six histologically negative disease-free patients were alive for 95 to 190 weeks. One of the patients who refused surgery after radiation and chemotherapy was alive at 4 years.
The Wayne State group 45 further modified this regimen and substituted cisplatin instead of mitomycin C. The results revealed that 19 of 21 patients underwent surgery and 27% attained pathologic complete response (CR) in the resected specimen, with a median survival of 18 months overall and a disease-free survival of 24 months. Spurred by the successes, RTOG and the Southwest Oncology Group (SWOG) initiated trials (Table 9) . 44 -51 In the RTOG 81-11 trial, 49 41 patients were treated with radiation (30 Gy/3 wks) and concurrent cisplatin plus short-course 5-FU infusion preoperatively. An additional 20 Gy of radiation was delivered postoperatively with 5-FU if tumor was present in the resected specimen. Eight (30%) of 27 who underwent resection had a pathologic CR. The overall two-year survival was 15% compared with 33% for those who had a pathologic CR. A 5% chemoradiation-related mortality was noted. In the SWOG 80-37 study, 48 33% (18 of 55 undergoing surgery) had a pathologic CR with a 45% projected survival at 3 years. Significant postoperative mortality of 11%, possibly reflecting surgical experience in this arena, was noted. In the ECOG 72-90 neoadjuvant chemoradiation study, 50 33 of 46 underwent resection; 24% (8 of 33) had a pathologic CR with a median survival of 16.8 months. Table 9 briefly summarizes these trials.
Four randomized trials (Table 10 ) addressing the role of neoadjuvant chemoradiation vs surgery have been conducted. 52 -55 The Dublin study 52 involved only patients with adenocarcinoma. Patients were to receive either surgery alone or two courses of neoadjuvant chemotherapy (cisplatin/5-FU) with concurrent RT 40 Gy/2.67 Gy per fraction. There was a 22% pathologic CR (13 of 58 patients) from neoadjuvant chemoradiation. A statistically significant survival benefit was noted for the chemoradiation cohort with a median survival of 16 months vs 11 months based on the intent to treat analysis and 32 months vs 11 months based on an analysis of actual treatment received. Three-year survival was also statistically significant favoring the chemoradiation arm (32% vs 6%). The study from the University of Michigan 55 randomized 100 patients with 50 patients in each arm to surgery alone and neoadjuvant chemoradiation (37.5 Gy/15 fractions and 45 Gy/1.5 Gy BID/3wks with cisplatin + 5-FU + vinblastine) and reported a three-year survival advantage with neoadjuvant chemoradiation (32% vs 15%, respectively, P=0.0734 log rank, P=0.0402 Cox regression). Local recurrence was also decreased by half in the combined-modality group (19% vs 39%, respectively, P=0.039). The studies on neoadjuvant chemoradiation have shown that pathologically confirmed CR ranging from 10% to 28% could be obtained with modest doses of radiation and concurrent chemotherapy. The survival in those who respond is significantly better than nonresponders, and the long-term survivors in these studies were those patients with a pathologic CR. Neoadjuvant chemoradiation appears to represent a step forward in achieving local control of disease. The CALGB study 9781 (RTOG 9716) is a prospective, randomized phase III trial comparing trimodality therapy to surgery alone. The protocol utilizes cisplatin 100 mg/m 2 bolus intravenous infusion on days 1 and 29, 5-fluorouracil 1000 mg/m 2 continuous intravenous infusion on days 1-4 and days 29-32, radiotherapy 50.4 Gy/1.8 Gy/5 weeks with a boost of 5.4 Gy on days 36-38, and surgery three to eight weeks following chemoradiation therapy. In the surgery-alone arm, surgery is performed within six weeks following randomization. The study seeks to compare the response, survival, and patterns of failure of trimodality therapy to surgery alone in a multi-institutional setting. Further trials in this area are needed to clarify the issue.
Radiotherapy has a number of roles in the treatment of patients with esophageal carcinoma. A number of approaches have been attempted over the last couple of decades to treat patients with carcinoma of the esophagus in order to reduce the local tumor burden and treatment of micrometastatic disease. These include various combinations of RT, surgery, and chemotherapy. The use of RT in a preoperative setting may improve resectability. The risk of locoregional failure is likely to be decreased with preoperative and postoperative RT. Clinical trials in the areas have not translated into improvement in survival. Definitive chemoradiation has shown promising results and appears to be superior to RT as the sole modality. Recent reports on neoadjuvant chemoradiation followed by surgery may represent a step forward in the local control of this neoplasm, especially in patients with adenocarcinoma. RT offers significant palliation in patients with inoperable disease and is extremely useful in such a setting. There is a need for enrolling patients in sufficient numbers in prospective clinical trials that will allow clinicians to be able to define the optimal sequencing and actual necessity of each individual component of combined-modality therapy.
New Directions
Currently, several active protocols are studying different therapeutic regimens. The US Gastrointestinal Intergroup-0123 protocol that is accruing patients is comparing chemoradiotherapy using cisplatin/5-FU with conventional-dose vs high-dose radiotherapy. CALGB-9781 is an effort to test neoadjuvant chemoradiation vs surgery alone and started accrual in 1997. All clinicians are encouraged to enter patients in clinical trials to improve the therapy of esophageal cancer.
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